COVID-19 Therapeutics Accelerator
The COVID-19 Therapeutics Accelerator (CTA) is self-described as “a philanthropic collaboration supporting efforts to research, develop and bring effective treatments against COVID-19 to market quickly and accessibly.”1)
Collaborators
CTA is co-funded by the Bill & Melinda Gates Foundation, Wellcome Trust and Mastercard, and was announced on March 10, 2020.2) 3) The initial funding was $125 million.4)
By the end of March, a number of pharmaceutical and biotechnology companies announced their participation. Those companies were BD, Boehringer Ingelheim, bioMerieux, Eisai, Eli Lilly, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck (both the US and German divisions), Novartis, Pfizer, and Sanofi.5)
In April 2020, announced that the United Kingdom government, the Chan Zuckerberg Initiative and Madonna had joined as funders. CZI provided an additional $20 million, with a further $5 million available “based on future needs”. The size of the UK government and Madonna's contributions were not disclosed.6)
External links
1)
Advancing research into accessible coronavirus treatments. COVID-19 Therapeutics Accelerator. Retrieved July 7, 2021, from https://archive.ph/5RTn4
2)
Suzman, M. (2020, March 10). Announcing the COVID-19 Therapeutics Accelerator. Bill & Melinda Gates Foundation. https://archive.ph/Z8Q5l
3)
COVID-19 Therapeutics Accelerator. (2020, March 10). Bill & Melinda Gates Foundation. https://archive.ph/uXOjt
4)
, 6)
Au-Yeung, A. (2020, April 3). A Bill Gates-Backed Accelerator For COVID-19 Therapeutics Treatment Partners With Madonna And Mark Zuckerberg’s Chan Zuckerberg Initiative. Forbes. https://archive.ph/WGnvO
5)
Staines, R. (2020, March 26). Pharma giants including Novartis collaborate on COVID-19 therapies. Pharmaphorum; Pharmaphorum Media Limited. https://archive.ph/8TAzM